besid
hereditari
atop
predisposit
viral
asthma
cal
bacteri
infect
respiratori
tract
may
contribut
asthma
tradit
defin
clinic
ground
preval
asthmat
symptom
either
simpl
trigger
respiratori
diseas
character
recurr
revers
airacut
exacerb
signific
contributor
pathogenway
obstruct
wheez
cough
dyspnea
recent
esi
airway
inflamm
hyperrespons
articl
year
understand
asthma
expand
special
focus
factor
childhood
asthma
wheez
impact
airway
inflamm
sever
case
airway
comment
diagnost
issu
avail
treatment
option
remodel
pathogenesi
led
new
definit
describ
asthma
chronic
inflammatori
process
may
repres
transient
earli
wheezer
although
transient
number
cell
cellular
event
involv
review
earli
wheezer
found
normaltosubnorm
lung
yang
function
age
year
children
asthmat
symptom
alreadi
show
signific
impair
expiratori
flow
volum
repeat
measur
gener
index
airway
uncertainti
howev
diagnosi
asthma
younger
chilresist
pef
measur
larg
airway
resist
dren
must
result
undertreat
antiinflammatori
account
total
resist
gain
global
control
drug
addit
shortact
consensu
guid
therapeut
intervent
patient
year
agonist
reliev
drug
age
bronchial
hyperreact
defin
decreas
mgml
methacholin
challeng
increas
differenti
diagnosi
administr
albuterol
salbutamol
patient
baselin
airflow
obstruct
particularli
infant
young
children
import
methacholin
challeng
perform
differenti
diagnos
exclud
recurr
wheezpati
asthma
also
exhibit
elev
level
fraction
ing
attribut
bronchial
hyperreact
asthma
chilexh
nitric
oxid
util
marker
airway
dren
receiv
full
set
vaccin
first
inflamm
measur
fraction
exhal
nitric
year
life
whoop
cough
alway
exclud
oxid
shown
enhanc
diagnosi
asthma
detect
droplet
precaut
implement
long
result
deterior
control
asthma
monitor
respons
bordetella
pertussi
diagnost
pend
antiinflammatori
therapi
level
decreas
inhal
cortian
aspir
foreign
bodi
may
caus
recurr
episod
costeroid
treatment
especi
individu
asthma
pulmonari
infect
make
reason
confirm
atopi
measur
fraction
exhal
nitric
oxid
clinic
diagnosi
pneumonia
chest
xray
hospitalmay
becom
import
tool
clinic
practic
furthermor
ize
children
also
control
complet
resolut
increas
sputumassoci
immun
cell
particular
pulmonari
infiltr
week
cystic
fibrosi
also
eosinophil
count
taken
account
diagnosi
exclud
sweat
test
child
sever
recurr
respirasinc
believ
reflect
underli
airway
inflamm
tori
tract
infect
eosinophil
count
also
use
predict
asthma
control
medic
histori
patient
may
reveal
prematur
discontinu
inhal
corticosteroid
prolong
ventil
supplement
oxygen
therapi
subsequ
bronchopulmonari
dysplasia
gastroesophag
reflux
recurr
wheez
versu
asthma
eas
nocturn
attack
wheez
cough
may
trigger
recurearli
childhood
rent
wheez
respiratori
infect
due
microaspir
sinus
caus
posterior
drainageassoci
chronic
cough
risk
subsequ
asthma
infant
first
episod
consid
school
age
children
asthma
sympof
wheez
difficult
predict
nearli
event
tom
chronic
persist
infect
airway
atyp
trigger
viral
infect
particular
respiratori
bacteria
mycoplasma
spp
chlamydophila
spp
may
syncyti
viru
rsv
human
metapneumoviru
hmpv
paraincaus
recurr
wheez
episod
beyond
simpl
acut
exfluenza
viru
piv
influenza
viru
iv
rhinoviru
adeacerb
recent
line
evid
suggest
infect
noviru
adv
hmpv
rsv
particular
also
rhiwith
atyp
bacteria
may
play
addit
role
novirus
may
contribut
acut
exacerb
asthma
pathogenesi
asthma
infect
may
repres
initi
event
histori
asthma
howev
consid
plethora
viral
agent
infant
endogen
exogen
risk
factor
immatur
immun
system
confront
shield
matern
deriv
antibodi
wane
recurr
wheez
may
result
continu
research
number
potenti
risk
consequ
recurr
infect
case
factor
eg
tobacco
smoke
hous
dust
mite
mould
pet
cockrsv
hmpv
even
reinfect
contrast
younger
chilroach
allergen
genet
background
atopi
developdren
major
children
age
year
hospit
ment
asthma
increas
review
arruda
et
al
acut
wheez
show
characterist
atopi
medic
breastfeed
altern
use
document
hyhistori
poallergen
formula
least
month
seem
protecit
import
therefor
emphas
recurr
wheez
tive
effect
may
explain
observ
rare
result
final
diagnosi
asthma
children
year
matern
intak
probiot
lactobacillu
rhamnosu
gg
late
pregnanc
follow
administr
l
rhamnosu
ed
misus
antibacteri
may
bias
studi
gg
infant
first
month
life
significantli
evalu
antibacteri
treatment
earli
infanc
risk
decreas
proport
children
atop
eczema
factor
subsequ
asthma
howev
note
verum
group
thu
gut
microflora
might
hitherto
unexin
contrast
misus
sophist
use
antibacteri
plore
sourc
natur
immunomodul
probiot
particular
macrolid
may
downregul
prolong
inflamm
prevent
atop
diseas
howev
protect
effect
increas
mucu
clearanc
prevent
biofilm
format
also
frequent
earli
exposur
potenti
pathogen
infect
decreas
bacteri
virul
review
shinkai
preval
asthma
question
studrubin
i
therebi
one
prospect
trial
foster
hypothesi
antibacteri
treatment
infanc
relat
higher
risk
asthma
later
life
nevertheless
mani
wheez
episod
infant
trigger
report
patient
compar
children
long
time
believ
respiratori
virus
rsv
rhinoviru
infect
oxygen
satur
sole
respons
common
cold
seriou
airway
valu
lower
children
rsv
infect
diseas
high
risk
patient
prematur
born
infant
signific
differ
respiratori
rate
score
combin
elderli
immunocompromis
subsequ
wheez
retract
children
rhinoviru
infect
wide
recogn
viral
respiratori
infect
may
caus
older
median
vs
month
present
often
sever
lower
respiratori
tract
diseas
immunocompet
indiatop
dermat
ci
blood
eosividu
addit
viral
respiratori
tract
infect
close
nophilia
ci
group
differ
link
wheez
infanc
hospit
acut
regard
total
serum
ige
risk
wheez
year
age
comparison
larg
subsequ
asthma
increas
rsvinduc
major
wheez
children
age
year
display
addit
wheez
rhinovirusinduc
wheez
atop
characterist
may
critic
risk
factor
recent
patient
collect
hospit
advers
respons
viral
infect
espelemansk
et
al
investig
role
rsv
infect
cialli
rhinoviru
preval
caus
agent
age
prospect
follow
birth
year
age
cohort
group
asthmat
children
bronchial
hyperrespons
children
genet
high
risk
develop
allerg
respiratori
singl
natur
cold
found
last
week
diseas
viral
etiolog
consid
firstyear
wheezbeyond
rsv
rhinoviru
newli
detect
virus
hmpv
ing
ill
caus
rhinoviru
infect
strongest
human
coronaviru
human
bocaviru
predictor
subsequ
thirdyear
wheez
p
may
substanti
contribut
acut
asthma
exacerb
moreov
infant
wheez
rhinoviru
sever
clinic
cours
viral
bronchiol
infant
season
continu
wheez
third
year
life
compar
link
inherit
abnorm
pulmonari
function
infant
p
also
certain
risk
factor
like
chronic
lung
diseas
prematur
similar
mechan
specul
activ
sever
hemodynam
relev
congenit
heart
diseas
neurolog
bronchiol
caus
rhinoviru
evid
rhiimpair
immunodefici
noviruslik
rsv
contribut
pathogenesi
asthma
addit
acut
aggrav
preexist
airway
childhood
consist
requir
investig
diseas
rsv
infect
lower
respiratori
tract
infant
prospect
trial
sever
enough
caus
hospit
link
subsejuntti
et
al
show
children
hospit
rsv
infecqu
bronchial
hyperreact
recurr
wheez
asthma
tion
infanc
still
differ
interferon
ifn
solubl
school
age
children
age
year
interestingintercellular
adhes
product
ly
children
recurr
wheez
first
rsv
year
infect
data
children
admit
oliti
display
elev
ige
antibodi
common
respiratohospit
rsv
infect
first
year
life
suggest
ry
food
allergen
well
thu
specul
pathogenesi
asthma
wheez
earli
rsv
lower
respiratori
tract
infect
rsv
trigger
gener
shift
infect
may
differ
children
without
earli
immun
system
favor
atopi
domin
helper
rsv
infect
latent
chronic
inflammatori
state
type
respons
upregul
ige
product
higher
level
airway
asthmat
atop
individu
may
allevi
infecinterleukin
il
bronchial
secret
rhinoviru
due
increas
express
tion
similar
chang
immun
system
hitherto
known
key
receptor
rhinovirus
implic
devast
consequ
first
rsv
necessari
adhes
respiratori
epithelium
immun
campaign
formalininactiv
rsv
vaccin
result
sever
even
lethal
ill
immun
children
diagnost
viral
respiratori
tract
infect
reli
seri
recent
public
retrospect
studi
differ
method
gener
depend
skill
kuopio
univers
hospit
finland
rhinovirus
deexperi
virolog
laboratori
tect
respiratori
sampl
children
hospit
wheez
infanc
singl
viral
fortun
virus
caus
respiratori
infect
find
rhinovirus
associ
develop
cultiv
permiss
cell
cultur
provid
asthma
year
later
p
odd
ratio
ci
necessari
equip
technolog
avail
howev
cultur
method
sometim
timeconsum
virus
respiratori
infect
infant
contribut
atyp
bactemay
extrem
difficult
recov
eg
case
hcovrial
pathogen
incept
asthmat
symptom
age
hmpv
rapid
diagnost
method
group
might
underestim
recent
publish
review
like
revers
transcriptas
polymeras
chain
reaction
rtpcr
johnston
martin
issu
includ
nine
studi
antigen
detect
assay
prefer
clinic
practic
antigen
pediatr
patient
tabl
ii
well
studi
adult
detect
enzymelink
immunosorb
assay
elisa
main
result
trial
children
includ
tabl
ii
method
avail
rsv
iv
piv
adv
provid
johnston
martin
came
conclus
posit
neg
result
minut
hour
studi
relationship
evid
asthma
infect
howev
assay
develop
routin
use
pneumonia
c
pneumonia
newli
detect
pathogen
like
hmpv
hcov
c
pneumonia
respiratori
pathogen
distribut
worldwid
method
choic
detect
viral
nucleic
acid
thu
pcr
caus
conjunct
pharyng
bronchiti
pneumortpcr
play
crucial
role
detect
newli
detect
nia
pleural
effus
case
subacut
onset
viral
respiratori
pathogen
agent
howev
prolong
period
convalesc
ongo
malais
still
unknown
long
pcr
remain
posit
respiratori
cough
characterist
symptom
acut
sinus
often
specimen
cessat
clinic
ill
accompani
acut
infect
c
pneumonia
caus
role
besid
high
sensit
rtpcrpcr
method
chronic
sinus
school
age
children
question
advantag
detect
addit
infect
anoth
viru
nearli
communityacquir
pneumonia
children
commonli
describ
coinfect
howev
viral
rna
year
age
caus
c
pneumonia
highest
incid
may
take
week
disappear
nasal
mucu
eg
found
schoolag
children
adolesc
onset
symptomat
respiratori
infect
rhinovirus
adult
display
serum
igg
antibodi
pathogen
may
clear
virus
detect
respons
oblig
intracellular
parasit
bacterium
util
energi
clinic
symptom
therefor
durat
detect
metabol
human
host
cell
replic
c
investig
avoid
fals
posit
pcr
result
week
pneumonia
transmit
direct
contact
droplet
possibl
month
first
infect
much
lesser
extent
aerosol
nuclei
fomit
condit
high
rel
humid
incub
period
approxim
day
attack
rate
rel
low
even
famili
bacteri
infect
contact
infect
c
pneumonia
usual
follow
specif
immun
respons
igm
igg
iga
antibodi
chronic
respiratori
tract
infect
may
contribut
certain
bacteri
antigen
humor
immun
respons
aggrav
symptom
patient
asthma
immunooblig
particular
infant
young
children
may
fail
logic
respons
infect
may
foster
develop
mount
suffici
antibodi
spite
cultureconfirm
infecbronchi
hyperreact
incept
new
atop
symptom
tion
thu
clear
whether
immun
respons
common
respiratori
allergen
chronic
inflamus
differenti
colon
infect
young
matori
remodel
process
airway
although
children
contribut
latter
remain
highli
specul
hahn
et
al
first
observ
wheez
hand
chronic
pulmonari
inflamm
deleteri
effect
adult
display
serolog
sign
infect
c
mucociliari
clearanc
drainag
mucu
cell
debri
pneumonia
find
extend
year
later
reduc
airway
patenc
enabl
develop
viral
group
suggest
detect
iga
antibodi
bacteri
superinfect
c
pneumonia
correspond
higher
probabl
recent
consensu
typic
bacteri
respiratori
pathogen
asthma
symptom
furthermor
schoolag
children
streptococcu
pneumonia
haemophilu
influenza
wheez
cunningham
et
al
observ
unusu
high
numhav
associ
exacerb
incept
ber
individu
lowgrad
c
pneumonia
infect
childhood
asthma
routin
administr
patient
asthma
exacerb
provid
signific
contrast
viral
respiratori
infect
c
pneumonia
conbenefit
tribut
rare
acut
asthma
exacerb
assoth
potenti
contribut
atyp
bacteria
particular
ciation
chronic
infect
c
pneumonia
mycoplasma
pneumonia
chlamydophila
pneumonia
subsequ
onset
asthma
suggest
author
onset
persist
childhood
asthma
still
matter
nagi
et
al
found
significantli
higher
risk
asthma
ongo
debat
emr
et
al
cultureposit
children
stabl
cultur
ige
c
pneumonia
detect
significantli
often
asthma
n
cultureneg
serolog
includ
igg
igm
cultureposit
asthmat
children
cultureneg
asthmat
children
cultureneg
mif
ige
eia
asthmat
children
control
vs
vs
p
control
p
respect
author
specul
product
specif
ige
c
pneumonia
may
foster
develop
asthma
cunningham
et
al
longitudin
studi
month
pcr
npa
eia
secretori
children
asthma
display
posit
c
mill
et
al
subject
prospect
birth
serolog
includ
igg
statist
signific
correl
symptom
cohort
studi
age
n
iga
mif
suggest
asthma
previou
month
either
igg
age
n
iga
antibodi
level
individu
high
igg
titer
even
show
protect
effect
ever
asthma
ci
conclus
c
pneumonia
major
risk
factor
esposito
et
al
airway
hyperrespons
rsv
infect
nagi
et
al
although
atyp
infect
link
prolong
asthmat
c
pneumonia
symptom
correl
infect
sever
chronic
asthma
asthma
exacerb
found
korppi
et
al
children
age
treat
mif
c
pneumonia
c
igg
antibodi
c
pneumonia
though
common
new
asthma
inpati
trachomati
antibodi
eia
children
detect
eia
differ
outpati
control
match
c
pneumonia
antibodi
newli
diagnos
asthma
patient
control
age
sex
municip
preval
iga
antibodi
eia
much
lower
likewis
differ
patient
control
biscardi
et
al
nosebind
lectin
allel
confirm
pcr
particular
detect
rhinoviru
import
viral
pathogen
asthma
exacerb
schoolag
children
chronic
infect
confirm
posit
igg
iga
antibodi
mill
et
al
howev
could
determin
signific
correl
c
pneumonia
serolog
asth
tabl
ii
retrospect
natur
antibodi
seri
detail
investig
clinic
laboratodetect
store
serum
sampl
result
cultur
pcr
ry
radiolog
present
communityacquir
pneumower
avail
identifi
patient
harbor
c
pneumonia
nia
children
age
year
reveal
combinain
airway
addit
individu
reportt
clinic
sign
host
acut
phase
respons
marker
cute
asthma
symptom
show
bronchial
hyperreact
valu
radiolog
find
reliabl
differenti
author
differenti
accord
two
age
group
bacteri
viral
atyp
typic
pneumonia
year
tabl
ii
author
emphas
discuss
age
group
thu
microbiolog
diagnost
effort
seroconvers
univers
associ
clinic
indispens
identifi
respons
respiratori
pathogen
infect
question
principl
assess
effect
initi
c
pneumonia
design
twar
strain
c
respiratori
infect
chronic
pulmonari
diseas
simpli
psittaci
differ
dna
sequenc
epidemiolog
measur
antibodi
titer
serum
also
pathogen
led
actual
classif
pathogen
contrari
two
group
found
invers
correl
befurthermor
high
preval
igg
antibodi
tween
c
pneumonia
respiratori
tract
infect
incept
c
pneumonia
gener
popul
adult
asthma
allerg
rhiniti
children
data
thu
laboratori
diagnosi
gener
base
serolog
role
c
pneumonia
incept
develop
asthma
test
children
intrigu
somewhat
controversi
well
result
consensu
confer
held
center
design
studi
need
one
recent
publish
studi
diseas
control
prevent
usa
dowel
colleagu
tabl
ii
detect
c
pneumonia
bronchoalveolar
conclud
acut
infect
c
pneumonia
accompani
lavag
bal
sampl
asthmat
children
pcr
also
appear
igm
antibodi
detect
confirm
viabil
pathogen
cultur
correl
week
onset
clinic
symptom
thereaft
igm
anan
elev
total
level
ige
lavag
cultur
posit
c
tibodi
detect
month
replac
low
pneumonia
author
conclud
viabl
c
pneumonia
titer
igg
antibodi
firstli
appear
week
infecfrequ
present
bal
specimen
symptomat
children
tion
dowel
colleagu
conclud
use
singl
asthma
paramet
lead
complet
diagnosi
pcr
although
yet
standard
increas
import
pneumonia
common
pathogen
upper
lower
futur
tool
diagnosi
furthermor
state
airway
infect
includ
otiti
media
pharyng
tracheno
wholli
satisfactori
serolog
method
diagnosi
c
obronch
pneumonia
age
group
older
pneumonia
infect
month
pneumonia
extracellular
mucos
pathogen
attach
respiratori
epithelium
via
specif
part
cell
pcr
method
pathogen
detect
increas
importh
organel
extent
invad
replic
intanc
second
atyp
bacteri
pathogen
relat
asthma
tracellularli
vivo
known
cellular
humor
pneumonia
howev
major
obstacl
use
pcr
immun
respons
infect
respons
clinic
ill
singl
method
detect
pneumonia
c
airway
injuri
acut
infect
accompani
lymphocyt
pneumonia
distinguish
viabl
prolifer
releas
tumor
necrosi
factor
tnf
nonviabl
bacteria
exampl
antibacteri
variou
interleukin
py
thu
least
one
method
recommend
laboratori
diagnosi
infect
howev
distinct
role
pneumonia
asthma
pathoth
frequent
use
method
detect
specif
antibodi
genesi
still
resolv
biscardi
colleagu
major
studi
investig
associ
report
highest
preval
pneumonia
infect
asthma
c
pneumonia
infect
children
first
asthma
attack
children
nofluoresc
test
altern
serolog
assay
previous
diagnos
asthma
acut
sever
exacerb
describ
lack
commerci
avail
limit
although
author
search
virus
use
pcr
specif
crossreact
antibodi
imped
broader
method
immunofluoresc
assay
avail
use
practic
laboratori
diagnosi
pneumonia
complex
author
develop
pneumoplex
assay
combin
multiand
even
difficult
although
pneumonia
cultivatplex
pcr
hybrid
assay
highli
specif
ed
solid
media
growth
extrem
slow
day
highli
sensit
cultur
method
extrem
insensit
thu
difficult
prevent
treatment
viral
infect
get
rapid
diagnost
result
method
howev
pneumonia
isol
swab
retronas
aspir
almost
year
first
descript
rsv
physician
sputum
bal
case
subsequ
cultur
attend
children
viral
respiratori
tract
diseas
asthma
pathogen
requir
desir
specimen
solv
still
await
develop
effect
econom
ie
materi
mix
medium
adequ
transporinexpens
medic
prevent
treatment
retat
media
rapid
detect
materi
investig
spiratori
viral
infect
infant
major
respirawith
enzym
immunoassay
oligonucleotid
hybrid
methtori
virus
specif
therapi
avail
imped
od
pcr
assay
infect
inhibit
viral
replic
infect
host
cultur
solidphas
media
middles
granul
case
treatment
symptomat
specif
intervent
coloni
without
typic
fri
egg
appear
form
fight
pathogen
contrast
bronchiol
hospit
orient
pneumonia
identifi
via
glucos
cleavag
infant
children
without
histori
asthma
recurr
reaction
hemadsorpt
hemolysi
final
identifiwheez
earli
administr
system
corticostec
procedur
finish
growth
inhibit
test
andor
roid
repres
primari
mean
treatment
sever
asthma
epifluoresc
insensit
cultur
method
exacerb
neuraminidas
inhibitor
oseltamivir
zanamivir
assay
gener
limit
imposs
activ
influenza
virus
avail
treatment
differenti
antibodi
subclass
ii
lack
specif
thu
microbiolog
confirm
influenza
substanc
iii
differenti
acut
chronic
previou
infecinhibit
enzymat
activ
neuraminidas
thought
tion
meanwhil
commonli
use
serolog
test
reprev
releas
newli
bud
progeni
virion
cell
place
complement
fixat
elisa
method
surfac
neuraminidas
inhibitor
use
earli
major
advantag
assay
commerci
avail
within
first
hour
cours
diseas
even
test
specif
differenti
differ
stage
chemoprophylaxi
thu
rapid
laboratori
diagnost
test
infect
detect
viral
rna
viral
antigen
mandatori
guid
decis
treatment
diagnosi
atyp
respiratori
tract
infect
anoth
possibl
prevent
influenzatrigg
asthma
still
labori
sophist
expens
time
consum
prevent
infect
vaccin
although
possibl
urgent
need
sensit
specif
standard
highli
desir
major
disadvantag
vaccin
target
econom
inexpens
diagnost
test
use
actual
influenza
strain
epidem
season
new
strain
bedsid
least
yield
result
within
hour
emerg
recent
observ
avian
influenza
viru
pathogen
easili
identifi
detect
definit
new
specif
vaccin
must
develop
gener
attribut
infect
vs
colon
possibl
avail
middl
ongo
epidem
confirm
role
incept
chronic
inflammatori
next
epidem
season
howev
strongli
recommend
vaccinaprocess
prospect
random
studi
best
therapeut
tion
highrisk
group
especi
increas
risk
intervent
perform
modern
multiplex
pcr
asthma
near
futur
newer
vaccin
formul
live
approach
detect
extend
spectrum
pathogen
parallel
attenu
influenza
vaccin
strain
may
complement
current
therebi
reduc
cost
materi
personnel
although
vaccin
strategi
approach
intrigu
realiti
check
publish
method
often
yield
much
lower
detect
rate
expect
specif
passiv
immunoprophylaxi
also
nonspecif
problem
probabl
overcom
recent
upgrad
antivir
therapi
avail
prevent
treat
infect
multiplex
assay
describ
khanna
et
al
human
rsv
first
option
immunoprophylaxi
palivizumab
human
monoclon
antibodi
bind
may
anoth
futur
option
treatment
rhinoviru
highli
conserv
f
protein
rsva
rsvb
subinfect
inhibit
attach
viru
host
cell
receptyp
efficaci
palivizumab
mainli
signific
reductor
uncoat
viral
nucleic
acid
pleconaril
tion
percentag
children
rehospit
appli
oral
distribut
upper
lower
airway
rsv
infect
first
month
life
test
two
enter
absorpt
infect
rhinovirus
howev
welldesign
prospect
random
doubleblind
mulnot
major
inclus
criterion
clinic
studi
ticent
studi
howev
prophylact
use
antibodi
pleconaril
limit
due
high
cost
thu
applic
recommend
import
cellular
receptor
attach
highrisk
prematur
infant
infant
hemodynamrhinovirus
experiment
approach
inhibit
ical
relev
congenit
heart
diseas
virusreceptor
interact
monoclon
antibodi
antagolevel
evid
rsvinfect
patient
allogen
blood
nistic
molecul
one
antibodylik
compound
cfi
stem
cell
transplant
recombin
antibodi
fusion
protein
may
promis
antivir
therapi
rsv
infect
possibl
sometim
candid
investig
clinic
trial
anoth
success
ribavirin
administ
inhal
compound
tremacamra
consist
deriaerosol
smallparticl
aerosol
gener
therapi
vate
transmembran
intracellular
domain
may
option
case
lifethreaten
rsv
infect
truncat
mechan
ventil
prematur
infant
sever
specif
therapi
vaccin
lack
human
immunocompromis
children
latter
group
ribavirin
metapneumoviru
respiratori
coronavirus
furthermor
suggest
treatment
option
patient
sever
data
experiment
usag
antivir
vitro
inhibit
influenza
parainfluenza
viru
infect
even
replic
virus
ambival
promhighrisk
popul
routin
use
controversi
due
ise
even
develop
specif
vaccin
yet
lack
evid
signific
benefit
random
control
studi
well
cost
issu
potenti
toxic
success
expect
teratogen
patient
expos
caregiv
one
human
metapneumoviru
untreat
studi
ribavirin
use
infant
sever
bronchiol
viral
pathogen
prospect
control
studi
need
conobserv
longterm
benefit
subsequ
airway
hyperfirm
refut
efficaci
therapeut
intervent
infant
reagibl
even
could
confirm
conand
children
recurr
wheez
asthma
bronchiol
troll
trial
valid
clinic
laboratori
paramet
indic
pneumonia
proven
prospect
random
subgroup
patient
experi
posit
doubleblind
studi
suffici
power
certain
therapeuoutcom
tic
intervent
posit
impact
ill
sever
breath
review
weinberg
number
compound
rate
oxygen
satur
length
inpati
care
known
display
margin
cytotox
effect
necess
admit
patient
intens
care
unit
start
highli
activ
rsv
inocul
tissu
cultur
three
mechan
ventil
also
import
identifi
evidencecompound
alreadi
test
phase
phase
ii
trial
base
treatment
method
avoid
unjustifi
consumpt
pleconaril
rsv
rf
howev
financi
resourc
context
system
treatment
cortineith
ribavirin
new
therapeut
agent
activ
costeroid
inhal
treatment
beta
mimet
rsv
assess
licens
use
children
adrenalin
epinephrin
investig
critic
recurr
wheez
asthma
exampl
epidemiolog
studi
publish
till
respiratori
virus
frequent
detect
schoolag
hmpvinfect
hospit
pediatr
patient
rechildren
asthma
rhinovirus
specif
ceiv
system
corticosteroid
half
treat
treatment
rhinovirus
avail
yet
increas
numbronchodil
due
increas
number
clinic
releb
promis
drug
candid
develop
even
vant
viral
respiratori
pathogen
also
increas
number
earli
phase
clinic
trial
one
drug
newli
develop
antivir
drug
absolut
prerequisit
success
pass
phase
ii
clinic
trial
rupintrivir
specif
treatment
remain
rapid
specif
diagnost
apselect
irrevers
inhibitor
rhinovir
proach
administ
intranas
peptidomimet
compound
specif
therapi
option
viral
infect
summar
poor
aqueou
solubl
low
oral
bioavail
anim
well
toler
healthi
adult
volunt
pleconaril
tabl
taken
togeth
result
itali
franc
support
use
antimicrobi
patient
asthma
microbiolog
confirm
pneumonia
c
pneumonia
infect
schmidt
et
al
recent
demonstr
children
therapyrefractori
bronchiti
pneumonia
bronchial
c
pneumonia
coinfect
associ
sever
diseas
studi
other
adequ
antibacteri
therapi
c
pneumonia
infect
shown
improv
pulmonari
function
figur
present
algorithm
manag
atyp
pulmonari
infect
patient
asthma
recurr
wheez
context
principl
aim
treatment
infect
erad
suppress
howev
seem
easi
achiev
c
pneumonia
infect
therefor
author
recommend
empir
second
cycl
treatment
symptom
persist
recur
relief
acut
symptom
patient
acut
infect
prompt
infect
selflimit
diseas
immunocompet
person
number
sever
recurr
wheez
exacerb
follow
reduc
inflammatori
stimulu
chronic
pulmonari
infect
atyp
pathogen
underli
pulmonari
diseas
stop
advers
effect
cellular
humor
immun
respons
bronchial
hyperreact
contain
microbiolog
target
oblig
intracellular
organ
c
pneumonia
bacteria
without
common
gramposit
gramneg
cell
wall
render
pathogen
priori
resist
glycopeptid
carbapenem
addit
pneumonia
suscept
sulfonamid
rifampicin
linezolid
firstlin
agent
treatment
infect
due
pneumonia
c
pneumonia
children
macrolid
erythromycin
clarithromycin
roxithromycin
azalid
azithromycin
erythromycin
clarithromycin
avail
also
individu
local
legal
restrict
may
limit
use
intraven
prepar
condit
child
antimicrobi
agent
allow
oral
medic
children
year
age
intraven
doxycyclin
may
use
feasibl
altern
although
thirdlin
agent
treatment
atyp
pneumonia
compar
studi
use
doxycyclin
children
sever
immunocompromis
children
adolesc
adolesc
besid
use
treatment
tickborn
fluoroquinolon
ie
levofloxacin
moxifloxacin
infect
melioidosi
brucellosi
howev
least
ketolid
telithromycin
due
potenti
toxic
licens
us
azithromycin
avail
intraven
use
issu
gener
consider
increas
select
pressur
clarithromycin
demonstr
scientif
reason
resist
pathogen
use
agent
standard
children
recurr
wheez
asthma
thu
beyond
may
combin
without
subsequ
problem
eg
exampl
scope
review
cyclosporin
stem
cell
organ
transplant
microbiolog
perspect
seem
reason
use
durat
treatment
clarithromycin
mgkgday
two
dose
least
day
firstlin
agent
display
promis
vitro
sensit
control
trial
avail
optim
durat
result
minimum
inhibitori
concentr
treatment
childhood
atyp
bacteri
tracheobronch
erythromycin
azithromycin
prospect
pneumonia
consid
observ
persist
colon
random
studi
children
treat
clarithromycin
convent
treatment
regimen
particular
c
test
erythromycin
ethylsuccin
mgkgday
two
pneumonia
infect
seem
reason
use
proor
three
divid
dose
patient
confirm
clinic
long
treatment
schedul
children
asthma
confirm
radiolog
success
erad
pneumonia
atyp
bacteria
infect
suggest
esposito
et
al
n
c
pneumonia
erad
cultur
azithromycin
ie
mgkgday
day
per
week
consecuth
gastrointestin
toler
clarithromycin
seem
tive
week
altern
use
clarithromycin
least
better
erythromycin
administ
twice
day
may
consid
well
design
randomdaili
ize
control
trial
clearli
need
examin
effecin
contrast
azithromycin
pharmacokinet
pattern
tive
differ
antibiot
pneumonia
c
clarithromycin
result
prolong
subtherapeut
plasma
pneumonia
optim
dose
durat
therapi
level
increas
risk
subsequ
colon
variou
patient
popul
macrolideresist
pneumococci
clinic
relev
observ
refut
other
argument
use
conclus
azithromycin
highli
activ
vitro
least
two
although
number
pathogen
suspect
associ
random
control
trial
children
confirm
efficaci
acut
chronic
asthma
pathogenesi
childhood
increassafeti
atyp
communityacquir
pneumonia
ing
number
option
specif
therapi
avail
children
find
color
tast
oral
suspens
azithroin
near
futur
also
increas
thu
start
therapi
mycin
agreeabl
drug
well
toler
adminisit
strongli
recommend
clinician
perform
rapid
clinic
tere
singl
daili
dose
addit
substanti
line
laboratori
diagnosi
accompani
detail
histori
evid
suggest
azithromycin
display
favor
immuthereaft
specif
individu
therapi
regimen
nomodulatori
antiinflammatori
effect
patient
consid
order
avoid
develop
resist
chronic
inflammatori
pulmonari
diseas
like
cystic
fibrominim
drugspecif
advers
effect
unnecessari
drug
intersi
bronchiol
obliteran
stem
cell
transplantaact
manner
treatment
may
avoid
acut
andor
chronic
tion
interestingli
esposito
et
al
investig
use
asthma
affect
patient
azithromycin
children
year
age
physician
diagnosi
recurr
respiratori
infect
result
